Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis

Area of Science:

• Pediatric Pulmonology
• Clinical Pharmacology

Background:

• Respiratory syncytial virus (RSV) bronchiolitis is a common childhood illness.
• Persistent cough and wheeze can occur after RSV bronchiolitis.
• Montelukast is a leukotriene receptor antagonist used for asthma and allergies.

Purpose of the Study:

• To investigate the long-term efficacy of montelukast in alleviating cough and wheeze symptoms post-RSV bronchiolitis in infants and young children.
• To assess the impact of montelukast on disease exacerbations and healthcare utilization.

Main Methods:

• A double-blind, prospective, randomized trial was conducted.
• Fifty-eight patients under 24 months hospitalized with their first RSV bronchiolitis episode were included.
• Participants received either montelukast (n=31) or a placebo (n=27) for 3 months.

Main Results:

• No statistically significant differences were observed between the montelukast and placebo groups in symptom-free or disease-free days/nights during the 3-month treatment period.
• Over a 1-year follow-up, the number of exacerbations, time to first exacerbation, unscheduled visits, and need for inhaled steroids were comparable between groups.
• Montelukast treatment did not demonstrate a significant benefit in reducing cough and wheeze symptoms or disease recurrence.

Conclusions:

• Montelukast treatment initiated after hospital admission for RSV bronchiolitis in children under two years old did not effectively reduce persistent cough and wheeze symptoms.
• The study suggests that montelukast is not broadly effective for this indication, although a potential benefit in a specific subgroup of children cannot be entirely ruled out.